Exploristics

Canaccord Genuity has advised Exploristics on its acquisition by MMS Holdings

Canaccord Genuity is pleased to announce that it has acted as the financial adviser to Exploristics, a Belfast-based tech-enabled biostatistics CRO, on its acquisition by MMS Holdings (MMS), a US-based data-focused CRO backed by Lindsay Goldberg, a US private equity firm.

The acquisition will add the company’s flagship product, KerusCloud®, a state-of-the-art, cloud-based statistical modelling and simulation platform to MMS’ data-driven approach towards efficient drug development.

With a history of strong organic growth, the acquisition of Exploristics positions MMS to enhance its global footprint and capabilities in advanced clinical trial design, innovative statistics, and data science. Building on its excellent track record in regulatory and end-game submissions, this acquisition now positions MMS a leader in biometrics and development strategy solutions for biotechnology and pharmaceutical sponsors of all sizes.